The product is a generic version of Lundbeck's Sabril powder for oral solution, Dr Reddy's said in a filing to the BSE.
The launch of Versavo is another step in that journey and helps in strengthening the company's oncology portfolio.
Pretomanid, a new chemical entity, was under development since 2002 by the TB Alliance.
Indian Pharmaceutical Alliance seeks to promote innovation backed by risk capital.
'This collaboration with CSIRIICT for developing new drugs is part of our broader strategy for enhancing our global specialty pipeline.'
The approved product is a generic version of Hygroton tablets, 25 mg and 50 mg of Sanofi Aventis US, LLC.
The United States Food and Drug Administration (USFDA) conducted inspection at Kothur facility between August 5-9, 2019.
The percentage increase in the median remuneration for the staff of the firm for FY19 was 3.96 per cent.
In the near term, the pharmaceutical company would continue to be driven by markets like India, Brazil and Canada.
The submission by the company came in response to a query by Justice Vibhu Bakhru as to what was it doing in cases where patients want more than the Rs 25 lakh.
The chairman of the Senate Finance Committee said this was needed as these facilities provided most of the ingredients for production inside the US.
Besides, the appellate tribunal also said that "the Liquidator cannot sell the assets of the premises in question."
Sources said the company’s R&D centre at Gurgaon (started by erstwhile Ranbaxy) will now undertake the clinical research handled by the Vadodara facility
On Monday, Pfizer and Mylan announced that as per the Reverse Morris Trust transaction, each Mylan share would be converted into one share of the new company.
USFDA had issued warning letter in November 2015 relating to Current Good Manufacturing Practice deviations at DR Reddy's API manufacturing facilities at Srikakulam.
Sihuan will leverage its over 4,000 strong sales force and 3,000 plus distributors across Mainland China to market the products.
Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service